The EMHA worked along KPMG on a market research to understand the patient journey and burden of disease for migraine in 12 countries. The Access to care survey 2021 has shown insightful results on the patients’ access to treatment and care in each of their country.
Summary of the “Access To Care III” survey results
•Majority of responders are women between 25 and 59 years old, actively working, from urban areas and with low family incomes (44% reported family annual incomes below 40K€).
•Almost 50% of responders reported suffer chronic migraine. Main indicators related to the type of migraine evidence that responders are, in average, patients suffering from severe migraine (57% with more than 8 days of migraine/month) for many years (83% responders suffer migraine for more than 10 years).
•Patients reported that migraine affects their daily activities when suffering attacks, being driving the more critical.
•First visited specialist is the G.P (58%). Nevertheless, the main specialist who made the diagnosis and the current follow up is the Neurologist (48% and 54% respectively). It is worth noting that a third of responders visited more than 4 specialist until being diagnosed, and a quarter reported not being followed by any HCP.
•Although 70% of responders do not go to a specialized migraine center, there is an overall agreement in that an increase of their availability would significantly improve migraine patients’ reality.
•Although almost 90% of patients are treated, time since diagnosis to treatment evidences difficulties to access to migraine treatments (49% needed more than 3 years since diagnosis).
•Since diagnosis, the first treatments received are general analgesics followed by triptans. The last prescribed are Anti CGRPs. Currently, the main treatments used are triptans (78%), and the least used Botox (11%). Nonetheless, polymedication is highly frequent and multiple drug combinations have been reported, being specific prescription mediations (e.g. triptans) alone or together with painkillers and/or topiramate the main received.
•The majority of those who do not take New Anti CGRPs treatment knows its existence (62%) and reported that the main barriers to its access is that their doctor didn’t mention it (26%), it is not covered by their health system (25%) or they are not eligible for the treatment yet (25%).
•For those patients treated with New Anti CGRPs, 25% reported to pay for the treatment out of their pocket. Almost a quarter of patients treated with New Anti CGRPs reported dissatisfaction with the treatment, being most of those responders suffering from severe migraine, mainly chronic, with more than 14 crisis per month.
•Despite more than half of responders reported that the cost of the treatment impacts on their finances (52%), most of them did not request a change for this reason. In fact, annual income does not affect their expenses in this sense as regardless of their income, responders are willing to pay as much money as they need to treat their migraine.